Interleukin Genetics (ILIU) 10-K 16 Mar 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 16, 2016	Jun. 30, 2015
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Registrant Name	INTERLEUKIN GENETICS INC
Entity Central Index Key	1,037,649
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 5,267,683
Trading Symbol	ILIU
Entity Common Stock, Shares Outstanding		172,953,440

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 4,706,018	$ 11,466,807
Accounts receivable from related party	39,989	23,544
Trade accounts receivable	45,973	14,013
Inventory	124,583	171,575
Prepaid expenses	778,970	504,719
Total prepaid expenses and other current assets	5,695,533	12,180,658
Fixed assets, net	643,900	773,779
Intangible assets, net	58,879	195,765
Other assets	93,208	116,919
Total assets	6,491,520	13,267,121
Current liabilities:
Accounts payable	408,374	513,927
Accrued expenses	497,688	343,225
Deferred revenue	3,238,541	3,154,498
Short term debt	1,333,333	0
Total current liabilities	5,477,936	4,011,650
Long term debt	3,474,984	4,738,614
Total liabilities	8,952,920	8,750,264
Stockholders’ equity:
Convertible preferred stock, $0.001 par value - 6,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2015 and 2014, respectively	0	0
Common stock, $0.001 par value - 450,000,000 and 300,000,000 shares authorized; 172,887,221 and 172,683,342 shares issued and outstanding at December 31, 2015 and 2014, respectively	172,889	172,686
Additional paid-in capital	126,354,036	125,434,483
Accumulated deficit	(128,988,325)	(121,090,312)
Total stockholders’ equity(deficit)	(2,461,400)	4,516,857
Total liabilities and stockholders’ equity (deficit)	$ 6,491,520	$ 13,267,121

BALANCE SHEETS _Parenthetical_

BALANCE SHEETS [Parenthetical] - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Convertible preferred stock, par value	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	6,000,000	6,000,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	450,000,000	300,000,000
Common stock, shares issued	172,887,221	172,683,342
Common stock, shares outstanding	172,887,221	172,683,342

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Genetic testing	$ 1,155,980	$ 1,641,490
Other	284,930	168,828
Total revenue	1,440,910	1,810,318
Cost of revenue	1,414,113	1,435,377
Gross profit	26,797	374,941
Operating expenses:
Research and development	1,299,542	843,102
Selling, general and administrative	5,878,940	5,767,138
Amortization of intangibles	136,886	94,100
Total operating expenses	7,315,368	6,704,340
Loss from operations	(7,288,571)	(6,329,399)
Other income (expense):
Interest income	222	4,935
Interest expense	(609,664)	(11,250)
Total other expense	(609,442)	(6,315)
Loss before income taxes	(7,898,013)	(6,335,714)
Net loss	$ (7,898,013)	$ (6,335,714)
Basic and diluted net loss per common share (in dollars per share)	$ (0.05)	$ (0.05)
Weighted average common shares outstanding, basic and diluted (in shares)	172,813,224	123,768,139

STATEMENTS OF STOCKHOLDERS' EQU

STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Total	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2013	$ 5,253,222	$ 0	$ 122,449	$ 119,885,371	$ (114,754,598)
Balance (in shares) at Dec. 31, 2013		0	122,448,707
Net loss	(6,335,714)	$ 0	$ 0	0	(6,335,714)
Private placement of preferred stock	4,806,874	$ 0	$ 50,100	4,756,774	0
Private placement of preferred stock (in shares)		0	50,099,700
Horizon warrant	261,386	$ 0	$ 0	261,386
Employee stock purchase plan	32,154	$ 0	$ 137	32,017	0
Employee stock purchase plan (in shares)		0	134,935
Stock-based compensation expense	498,935	$ 0	$ 0	498,935	0
Balance at Dec. 31, 2014	4,516,857	$ 0	$ 172,686	125,434,483	(121,090,312)
Balance (in shares) at Dec. 31, 2014		0	172,683,342
Net loss	(7,898,013)	$ 0	$ 0	0	(7,898,013)
Private placement of preferred stock	(8,095)	0	0	(8,095)
Horizon warrant	14,810	0	0	14,810	0
Employee stock purchase plan	20,954	$ 0	$ 203	20,751	0
Employee stock purchase plan (in shares)		0	203,879
Stock-based compensation expense	892,087	$ 0	$ 0	892,087	0
Balance at Dec. 31, 2015	$ (2,461,400)	$ 0	$ 172,889	$ 126,354,036	$ (128,988,325)
Balance (in shares) at Dec. 31, 2015		0	172,887,221

STATEMENTS OF STOCKHOLDERS' EQ6

STATEMENTS OF STOCKHOLDERS' EQUITY [Parenthetical]	12 Months Ended
	Dec. 31, 2014USD ($)
Private placement, net of offering costs	$ 218,127

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
CASH FLOW FROM OPERATING ACTIVITIES:
Net loss	$ (7,898,013)	$ (6,335,714)
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities:
Depreciation and amortization	349,254	262,961
Amortization of loan issuance costs and FV of warrants	108,224	0
Stock-based compensation expense	892,087	498,935
Changes in operating assets and liabilities:
Receivable from related party	(16,445)	511,159
Trade accounts receivable	(31,960)	(5,196)
Inventory	46,992	18,849
Prepaid expenses and other assets	(274,251)	171,639
Accounts payable	(105,553)	(321,512)
Accrued expenses	154,463	90,272
Other Assets (lease deposit refund)	0	10,000
Deferred revenue	84,043	(628,943)
Net cash used in operating activities	(6,691,159)	(5,727,550)
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital additions	(82,489)	(98,033)
Net cash used in investing activities	(82,489)	(98,033)
CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds from issuance of notes payable	0	5,000,000
Loan origination costs	0	(88,918)
Proceeds from private placement of common stock and warrants	0	5,025,000
Private placement offering costs	(8,095)	(218,127)
Proceeds from employee stock purchase plan	20,954	32,154
Net cash provided by financing activities	12,859	9,750,109
Net increase (decrease) in cash and equivalents	(6,760,789)	3,924,526
Cash and cash equivalents, beginning of period	11,466,807	7,542,281
Cash and cash equivalents, end of period	4,706,018	11,466,807
Supplemental disclosures of cash flow information:
Cash paid for interest	467,500	0
Supplemental disclosures of non-cash investing and financing activities:
Warrants issued in connection with long term debt	$ 0	$ 261,386

Company Overview

Company Overview	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Basis of Presentation	Note 1—Company Overview Interleukin Genetics, Inc. (“Interleukin” or “the Company”) is focused on developing and commercializing personalized health products that can help individuals improve and maintain their health through preventive measures. It uses functional genomics to help in the development of risk assessment tests based on the genetic variations in people. Interleukin has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, general nutrition assessment, weight management and bone health. The Company’s current focus is on commercializing its periodontal genetic risk assessment test and its Inherent Health® brand of genetic tests which includes the Company’s Weight Management genetic test.

Operating Matters and Liquidity

Operating Matters and Liquidity	12 Months Ended
	Dec. 31, 2015
Going Concern [Abstract]
Operating Matters and Liquidity	Note 2—Operating Matters and Liquidity The Company has experienced net operating losses since its inception through December 31, 2015. The Company had net losses of $ 7.9 6.3 129.0 The Company continues to take steps to reduce genetic test processing costs. Cost savings are primarily achieved through test process improvements. Management believes that the current laboratory space is adequate to process high volumes of genetic tests. On May 17, 2013, the Company entered into a Common Stock Purchase Agreement (the “2013 Purchase Agreement”) with various accredited investors (the “2013 Investors”), pursuant to which the Company sold securities to the 2013 Investors in a private placement transaction (the “May 2013 Private Placement”). In the May 2013 Private Placement, the Company sold an aggregate of 43,715,847 0.2745 12,000,000 32,786,885 0.2745 On December 23, 2014, the Company entered into a Securities Purchase Agreement (the “2014 Purchase Agreement”) with various accredited investors (the “2014 Investors”), pursuant to which the Company sold to the 2014 Investors in a private placement transaction (the “December 2014 Private Placement”) an aggregate of 50,099,700 0.1003 5.025 50,099,700 0.1003 The Company’s financial statements have been prepared assuming that it will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company expects to incur additional losses in 2016 and, accordingly, is dependent on financings and potential revenue to fund its operations ® ® ® ® ® The Company expects to have the cash resources necessary to support the further commercialization of the ® test at least into the second half of 2016 The ability of the Company to realize the carrying value of its fixed assets and intangible assets is especially dependent on management’s ability to successfully execute on its plan. The Company needs to generate additional funds in order to meet its financial obligations. If it is unsuccessful in doing so, the Company may not be able to realize the carrying value of its fixed assets and intangible assets.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3—Summary of Significant Accounting Policies The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reported periods. Actual results could differ from those estimates. The Company’s most critical accounting policies are more fully discussed in these notes to the financial statements. Revenue from genetic testing services is recognized when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test. To the extent that tests have been prepaid but results have not yet been reported, recognition of all related revenue is deferred. As of December 31, 2015 and December 31, 2014, the Company had deferred genetic test revenue of $ 3.2 3.2 2.6 0.3 2.3 3.3 The Company recognizes breakage revenue related to genetic test kits utilizing the remote method. Under the remote method, breakage revenue should be recognized when the likelihood of the customer exercising rights of redemption becomes remote. The term remote requires statistical analysis of customer redemption patterns for all tests sold and returned. The Company analyzed redemption patterns from 2009 through 2015 and determined the period of time after which the likelihood of test redemption was remote was three years after the sale of a genetic test kit. Included in genetic test revenue in the years ended December 31, 2015 and 2014 is $ 218,000 309,000 On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor Inc. (“Alticor”). Pursuant to this Agreement, Amway Global sells the Company’s Inherent Health ® 302,000 218,000 Accounts receivable is stated at estimated net realizable value, which is generally the invoiced amount less any estimated discount related to payment terms. The Company offers its commercial genetic test customers a 2 Inventory Inventory is carried at lower of cost (first-in, first-out method) or market and no inventory reserve is deemed necessary at December 31, 2015. As the Company does not manufacture any products, no overhead costs are included in inventory. The Company has contracted with a fulfillment provider to supply its PerioPredict ® ® 33,000 ® ® December 31, 2015 December 31, 2014 Raw materials $ 112,372 $ 163,239 Finished goods 12,211 8,336 Total inventory, net $ 124,583 $ 171,575 The Company accounts for stock-based compensation expense in accordance with FASB ASC 718, Compensation – Stock Compensation The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes Significant management judgment is required in determining the Company’s provision (benefit) for income taxes, its deferred tax assets and liabilities and any valuation allowance recorded against deferred tax assets. The Company has recorded a full valuation allowance against its deferred tax assets of approximately $ 33.5 As a result of the Company’s change in its capital structure during the quarters ended June 30, 2013 and December 31, 2014, the Company may have undergone IRC section 382 ownership changes which would limit its ability to realize the benefit of its tax attributes (i.e., federal/state net operating losses and research and development credits) during their respective carry forward periods. Furthermore, pursuant to the change in capital structure in the quarter ended June 30, 2013, the Company realized cancellation of indebtedness income under IRC section 108(e)(8), which reduced the Company’s federal net operating loss carry-forward pursuant to IRC section 108(b)(2)(A), due to the fact that the Company’s liabilities exceeded the fair market value of its assets. Accordingly, the Company had a reduction in its deferred tax asset and a corresponding reduction in its valuation allowance for the quarter ending June 30, 2013. The cancellation of indebtedness income resulted from a shareholder’s conversion of debt of approximately $ 14.3 The Company reviews its recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. The Company reviews all material tax positions for all years open to statute to determine whether it is more likely than not that the positions taken would be sustained based on the technical merits of those positions. The Company did not recognize any adjustments for uncertain tax positions as of and during the year ended December 31, 2015. However, if the Company incurred interest and penalties they would be recorded in general and administrative expenses. Research and development costs are expensed as incurred. The Company applies the provisions of FASB ASC 260, Earnings per Share As of December 31, 2015 2014 Options outstanding 21,657,776 4,523,900 Warrants outstanding 88,301,079 89,951,079 Total 109,958,855 94,474,979 Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. During the years ended December 31, 2015 and 2014, there were no items other than net loss included in the determination of comprehensive loss. The Company, using available market information, has determined the estimated fair values of financial instruments. The stated values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to the short term nature of these instruments. The fair value of warrants is calculated using the Black-Scholes pricing model. The Company maintains its cash and cash equivalents with domestic financial institutions that the Company believes to be of high credit standing. The Company believes that, as of December 31, 2015, its concentration of credit risk related to cash and cash equivalents was not significant. Cash and cash equivalents are available on demand and are generally in excess of FDIC insurance limits. Fixed assets are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided using the straight-line method over estimated useful lives of three to five years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease. Assets that have not yet been placed in service, have the costs incurred presented as part of Projects in Progress. Once the asset has been placed in service, the related costs are transferred to the appropriate category and depreciation commences. There are no items in Projects in Process for the year ended December 31, 2015. The Company evaluates its long-lived assets, including intangible assets, for impairment whenever events or changes in circumstances indicate that carrying amounts of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. Any write-downs, based on fair value, are to be treated as permanent reductions in the carrying amount of the assets. For the year ended December 31, 2015, the Company recorded a write down of $ 66,000 As of December 31, 2015 and 2014, the Company has one segment, the genetic test business. The Company develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive measures. The Company’s principal operations and markets are located in the United States. FASB ASU 2015-03 - Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. In April 2015, the FASB issued ASU No. 2015-03, which requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts. Prior to the amendments, debt issuance costs were presented as a deferred charge (i.e., an asset) on the balance sheet. Further, the amendments require the amortization of debt issuance costs to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate on the debt. The amendments are effective for public business entities for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The amendments must be applied retrospectively. All entities have the option of adopting the new requirements as of an earlier date for financial statements that have not been previously issued. The Company does not expect this ASU to have a material impact on its consolidated financial statements. FASB ASC 606 ASU 2014-09 - Revenue from contracts with customers. In May 2014, the FASB issued amended guidance on contracts with customers to transfer goods or services or contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). The guidance requires an entity to recognize revenue on contracts with customers to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance requires that an entity depict the consideration by applying the following five steps: ⋅ Identify the contract(s) with a customer. ⋅ Identify the performance obligations in the contract. ⋅ Determine the transaction price. ⋅ Allocate the transaction price to the performance obligations in the contract. ⋅ Recognize revenue when (or as) the entity satisfies a performance obligation. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. This amendment is to be either retrospectively adopted to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. The Company is evaluating the impact of the adoption of this guidance to determine whether or not it has a material impact on the Company's financial statements. In April 2015, the FASB voted to defer the required implementation date of ASU 2014-09 to December 2017. Public companies may elect to adopt the standard along the original timeline. We are evaluating the impact of the adoption of this guidance to determine whether or not it has a material impact on the Company's financial statements. FASB ASC 606 ASU 2014-15 - Presentation of Financial Statements—Going Concern (Subtopic 205-40); Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern . In August 2014, the FASB issued ASU No. 2014-15, which applies should a company be facing probable liquidation within one year of the issuance of the financial statements, but is not actually in liquidation at the time of issuance. The applicable basis for presentation remains as a going concern, but if liquidation within one year is probable, then certain disclosures must be included in the financial statement presentation. ASU 2014-15 is effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. The Company is not electing to adopt early and is evaluating the impact of ASU 2014-15 on the Company’s financial disclosures.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Note 4—Related Party Transactions Since March 2003, the Company has maintained a broad strategic alliance with several affiliates of the Alticor Inc. family of companies, a related party, to develop and market novel nutritional and skin care products. The alliance initially included an equity investment, a multi-year research and development agreement, a licensing agreement with royalties on marketed products, the deferment of outstanding loan repayment and the refinancing of bridge financing obligations. On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor Inc. Pursuant to this Agreement, Amway Global sells the Company’s Inherent Health ® 302,000 218,000 Beginning in September 2012 and again in 2013, Access Business Group LLC (“ABG”), an affiliate of Alticor, placed purchase orders totaling approximately $ 3.3 1.5 1.8 519,000 250,000 On September 21, 2012, the Company entered into a License Agreement with Access Business Group International LLC (“ABGI”), an affiliate of Alticor. Pursuant to the License Agreement, the Company has granted ABGI and its affiliates a non-exclusive license to use the technology related to Interleukin’s Weight Management genetic test and to sell the Weight Management test in Europe, Russia and South Africa (the “Territories”). ABGI, or a laboratory designated by ABGI, will be responsible for processing the tests, and the Company will receive a royalty for each test sold, which royalty will increase if certain pending patent applications are issued. The License Agreement has an initial term of five years from the date of first commercial sale of the Weight Management test under the agreement which was June 2013. Thereafter, the term will automatically renew for additional one-year periods unless notice is delivered by either party at least 60 191,000 150,000 In connection with the execution of the License Agreement, the Company and ABGI also entered into a Professional Services Agreement (the “PSA”) pursuant to which the Company has agreed to provide services to ABGI in connection with its sale and processing of the tests within the Territories. No fees were earned in the years ended December 31, 2015 and 2014 under the PSA. For years ended December 31, 2015 and 2014, approximately 45 44 13 32 On February 25, 2013, the Company entered into a Preferred Participation Agreement with Renaissance Health Services Corporation (“RHSC”), for itself and on behalf of certain of its affiliates and subsidiaries. This agreement was amended and restated on November 1, 2013. RHSC is a related party through its affiliation with Delta Dental of Michigan, Inc. (“DDMI”), a stockholder of the Company. ® unless terminated earlier . This agreement terminated on February 25, 2016.

Debt Instruments

Debt Instruments	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Debt Instruments	Note 5—Debt Instruments Venture Loan and Security Agreement On December 23, 2014, the Company entered into the Loan Agreement with Horizon Technology Finance Corporation (the “Lender”) under which the Company borrowed $ 5.0 The loan bears interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeds 0.50%, the interest rate will be adjusted by an amount equal to the difference between such rates at the end of that particular month. 9.0 The loan is to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan, or $225,000, will be due and payable. 2,492,523 0.1003 (10) Additionally, $ 89,000 261,000 225,000 257,000 456,000 11,000 153,000 0

Fixed Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2015
Assets [Abstract]
Fixed Assets	Note 6—Fixed Assets Useful Life 2015 2014 Computer software, computer equipment and office equipment 3 years $ 516,511 $ 477,222 Laboratory equipment 5 years 1,887,454 1,837,504 Furniture and fixtures 5 years 40,349 40,349 Leasehold improvements 5 years 309,618 309,618 Website development 3 years 298,553 298,553 Projects in Progress — 6,750 3,052,485 2,969,996 Less — Accumulated depreciation and amortization (2,408,585) (2,196,217) Total $ 643,900 $ 773,779 Depreciation and amortization expense was $ 212,000 169,000

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2015
Intangible Assets [Abstract]
Intangible Assets	Note 7—Intangible Assets 2015 2014 Patent costs $ 1,154,523 $ 1,154,523 Less — Accumulated amortization (1,029,497) (958,758) Less — Write off related to patents no longer in use (66,147) — Total $ 58,879 $ 195,765 Patent amortization expense was $ 136,900 94,100 10 Year ended December 31, 2016 33,450 2017 19,117 2018 6,312 $ 58,879

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2015
Accrued Liabilities, Current [Abstract]
Accrued Expenses	Note 8—Accrued Expenses Accrued expenses at December 31, 2015 and 2014 consisted of the following: 2015 2014 Payroll and vacation $ 412,674 $ 328,972 Other 85,014 14,253 Total accrued expenses $ 497,688 $ 343,225

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies [Abstract]
Commitments and contingencies	Note 9—Commitments and Contingencies Off-Balance Sheet Arrangements The Company has no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on its financial condition, results of operations or cash flows. Employment Agreements Mark B. Carbeau On April 6, 2015 the Company entered into an Executive Employment Agreement (the “Agreement”), pursuant to which Mark B. Carbeau was appointed as the Company’s Chief Executive Officer and a member of the Company’s Board of Directors. Effective upon Mr. Carbeau’s appointment, Dr. Kenneth S. Kornman resigned as Chief Executive Officer and remained as the Company’s President and Chief Scientific Officer. Pursuant to the Agreement, Mr. Carbeau will receive an initial annual base salary of $ 365,000 35 150 14,245,227 0.1525 25 2.083 The Agreement provides that if Mr. Carbeau’s employment with the Company is terminated for any reason other than Cause (as defined in the Agreement) and on execution of a release of claims agreement, he will be entitled to (i) severance payments equal to 12 months of base salary and (ii) continuation of medical benefits for up to 12 months. In addition to the above, if termination is within one year following a Change of Control event and is for any reason other than Cause, all outstanding unvested equity awards held by Mr. Carbeau will immediately vest and be exercisable. Kenneth S. Kornman, DDS, Ph.D. On November 12, 2008, the Company entered into an employment agreement with Dr. Kornman, its President and Chief Scientific Officer, for a three-year term, commencing on March 31, 2009, the date his previous employment agreement expired. Effective March 31, 2012, this agreement was extended through November 30, 2012, and was extended again on November 20, 2012 through November 30, 2015. Under this agreement, Dr. Kornman received an initial annual salary of $ 360,000 75,000 0.48 The Company entered into a new employment agreement with Dr. Kornman on December 1, 2015 (the “Agreement”), pursuant to which Dr. Kornman will receive an initial annual salary of $ 360,000 400,000 0.07 3,296 On March 31, 2010, Dr. Kornman was issued 12,500 30,000 0.745 20 In May 2011, the Compensation Committee granted Dr. Kornman an option to purchase 100,000 0.46 25 In December 2012, the Compensation Committee granted Dr. Kornman an option to purchase 300,000 0.34 25 33 42 In October 2013, Dr. Kornman was granted an option to purchase 2,250,000 0.3799 In January 2015, Dr. Kornman was granted an option to purchase 2,030,000 0.26 Scott Snyder On December 26, 2012, the Company entered into an employment agreement with Scott Snyder for the position of Chief Marketing Officer beginning on January 2, 2013. The agreement provides for a minimum annual base salary of $ 265,000 The Company will pay Mr. Snyder any compensation that is earned but unpaid prior to termination, and an amount equal to six months of his base salary in effect at the time of the termination with such payment made in equal installments on the Company’s regularly-scheduled payroll dates. All stock options granted to Mr. Snyder expired unexercised as of February 11, 2016. Bonus Plan On February 26, 2014, the Compensation Committee approved an Employee Bonus Plan (the “Employee Bonus Plan”) that replaces the Bonus Plan approved on December 21, 2012. Under the Employee Bonus Plan, bonuses may be awarded upon the achievement of corporate goals, however, the Compensation Committee has absolute discretion as to whether bonuses will be awarded and the size of any bonus, notwithstanding whether any such corporate goals are met. Bonus accruals totaling $ 166,000 Operating Leases The Company leases its office and laboratory space under a non-cancelable operating lease which was originally scheduled to expire on March 31, 2014. In May 2010, the Company completed a sublease of 6,011 square feet of underutilized office and laboratory space and on March 31, 2014, the sublease expired. On February 7, 2014, the Company entered into the Second Amendment to Commercial Lease which, among other things a) extended the term of the lease from March 31, 2014 to March 31, 2017; b) reduced the 19,000 square feet, the amount of space under the master lease, by approximately 6,011 square feet, to approximately 13,000 square feet, which is the amount of space the Company currently occupies; and, c) set an initial base rent with an escalation of 2.06% of base rent in year two and another 2.06% in year three. Future minimum lease commitments under non-cancelable lease agreements with initial or remaining terms of one year or more at December 31, 2015, are as follows: Year Ended Office Total December 31, Office Lease Copier Lease Net Lease Equipment Payments, Net 2016 326,349 6,624 332,973 2,226 335,199 2017 81,993 6,624 88,617 2,226 90,843 2018 — 1,104 1,104 1,484 2,588 $ 408,342 14,352 $ 422,694 $ 5,936 $ 428,630 Rent expense, net of the benefit of the sublease in 2014, was $ 352,682 309,891 2.06 2.06

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2015
Capital Stock [Abstract]
Capital Stock	Note 10—Capital Stock Authorized Preferred and Common Stock As of December 31, 2015, the Company has 6,000,000 0.001 450,000,000 0.001 172,887,221 Reserved for issuance Strike Price Expiry Shares reserved under outstanding stock options and options available for grant 52,307,279 Shares reserved for future issuance under the Employee Stock Purchase Plan 300,073 Warrants to purchase common stock associated with December 2014 private placement 50,189,431 $ 0.1003 December 23, 2021 Warrants to purchase common stock associated with December 2014 venture loan and security agreement 2,492,523 $ 0.1003 December 23, 2024 Warrants to purchase common stock associated with September 2014 consulting agreement with Danforth Advisors 100,000 $ 0.2500 September 8, 2024 Outstanding warrants issued in June 2012 437,158 $ 0.2745 June 29, 2017 Outstanding warrants issued in May 2013, vesting May 2013 20,655,737 $ 0.2745 May 17, 2020 Outstanding warrants issued in May 2013, vesting August 2013 14,426,230 $ 0.2745 August 9, 2020 Total common shares reserved for issuance at December 31, 2015 140,908,431 Total common shares issued and outstanding at December 31, 2015 172,887,221 Total common shares outstanding and reserved for issuance at December 31, 2015 313,795,652 On May 17, 2013, the Company entered into the 2013 Purchase Agreement with the 2013 Investors, pursuant to which the Company sold securities to the 2013 Investors in the May 2013 Private Placement. In the May 2013 Private Placement, the Company sold an aggregate of 43,715,847 0.2745 12,000,000 32,786,885 0.2745 63 37 150,000,000 300,000,000 For its services in this transaction, the placement agent received cash compensation in the amount of approximately $ 780,000 2,295,082 0.2745 In connection with this private placement, all preferred stockholders converted their shares of Preferred Stock to common stock resulting in the issuance of 39,089,161 In addition, pursuant to the 2013 Purchase Agreement, each Investor had the right, at any time on or before June 30, 2014 (the “Exercise Date”), to purchase at one or more subsequent closings its pro rata share of up to an aggregate of 18,214,936 0.2745 13,661,201 0.2745 In September, 2014, issued warrants to financial consultant, Danforth Advisors, to purchase up to 100,000 0.25 if the Company terminates the agreement without cause before the one year anniversary, 50 24,000 12,000 3,000 On December 23, 2014, the Company entered into the 2014 Purchase Agreement with the 2014 Investors, pursuant to which it sold to the 2014 Investors in the December 2014 Private Placement an aggregate of 50,099,700 0.1003 5.025 50,099,700 0.1003 For services related to this transaction, the placement agent and legal counsel received an aggregate of $ 218,000 89,731 December 23, 2014 Risk-free interest rate 1.98 % Expected life 7 years Expected volatility 138.4 % Dividend yield 0 % On the closing date of the December 2014 Private Placement, the fair value of the 2014 Warrants was $ 5.2 9,000 Registration Rights Agreements In connection with the December 2014 Private Placement, on December 23, 2014, the Company also entered into a Registration Rights Agreement with the 2014 Investors and the placement agent, pursuant to which the Company was required to file a registration statement on Form S-1 within 45 days of December 23, 2014 to cover the resale of (i) the shares of common stock sold to the 2014 Investors and the shares of common stock underlying the 2014 Warrants and (ii) the shares of common stock underlying the 2014 Placement Agent Warrants. The Company filed the registration statement on February 6, 2015, and it was declared effective on March 31, 2015. Venture Loan and Security Agreement On December 23, 2014, the Company entered into the Loan Agreement with Horizon Technology Finance Corporation (the “Lender”) under which the Company has borrowed $ 5.0 2,492,523 0.1003 The Lender Warrants were recorded as equity at fair value on the date of issuance. December 23, 2014 Risk-free interest rate 2.17 % Expected life 10 years Expected volatility 121.6 % Dividend yield 0 % The fair value of the Lender Warrants at issuance was $ 261,000 467,500 0 153,000 0 257,000 2016 1,333,333 2017 2,000,000 2018 1,666,667 $ 5,000,000

Stock-Based Compensation Arrang

Stock-Based Compensation Arrangements	12 Months Ended
	Dec. 31, 2015
Stock-Based Compensation Arrangements [Abstract]
Stock-Based Compensation Arrangements	Note 11—Stock-Based Compensation Arrangements On August 9, 2013, the Company’s shareholders’ approved the 2013 Employee, Director and Consultant Equity Incentive Plan (the “2013 Plan”). The 2013 Plan allows for the issuance of up to 8,860,000 2,435,500 6,570,748 30,000,000 30,649,503 Pursuant to his Employment Agreement on April 6, 2015, Mr. Carbeau was granted options to purchase up to 14,245,227 0.1525 2,622,948 11,622,279 Stock Option Grants It is the Company’s policy to grant stock options with an exercise price equal to the fair market value of the Company’s common stock at the grant date. Historically, the majority of the Company’s stock options have been granted in connection with the employee’s start date with the Company. In addition, the Company may grant stock options in recognition of promotion and/or performance. Nonqualified and incentive stock options with a life of 10 years are granted at exercise prices equal to the fair market value of the common stock on the date of grant. Options generally vest ratably over a period of three to five years based upon continuous service. 2015 2014 Risk-free interest rate 1.54 % 1.53 % Expected life 5.73 years 5.73 years Expected volatility 138.80 % 144.74 % Dividend yield 0 % 0 % Using these assumptions, the weighted average grant date fair value of options granted in 2015 and 2014 was $ 0.16 0.32 Restricted Stock Awards Holders of restricted stock awards participate fully in the rewards of stock ownership of the Company, including voting and dividend rights. Recipients of restricted stock awards are generally not required to pay any consideration to the Company for these restricted stock awards. The Company measures the fair value of the shares based on the last reported price at which the Company’s common stock traded on the date of the grant and compensation cost is recognized over the remaining service period. During each of the years ended December 31, 2015 and 2014, the Company granted no restricted stock awards. Employee Stock Purchase Plan Purchases made under the Company’s Employee Stock Purchase Plan are deemed to be compensatory because employees may purchase stock at a price equal to 85 203,879 134,935 0.10 0.24 0.12 0.28 4,053 5,437 2015 2014 Weighted Avg. Weighted Avg. Exercise Exercise Shares Price Shares Price Outstanding, beginning of period 4,523,900 $ 0.39 5,884,050 $ 0.43 Granted 18,193,027 0.17 137,000 0.35 Stock options exercised –– 0.00 –– 0.00 Restricted stock exercised –– 0.00 –– 0.00 Forfeited/Expired (1,059,151) 0.17 (1,497,150) 0.53 Outstanding, end of period 21,657,776 $ 0.21 4,523,900 $ 0.39 Exercisable, end of period 3,665,124 $ 0.32 1,645,161 $ 0.43 Stock Options/Restricted Stock Stock Options/Restricted Stock Outstanding Exercisable Weighted Avg. remaining Weighted Avg. Weighted Avg. contractual life Exercise Exercise Range of Exercise Price: Shares (years) Price Shares Price $0.01–$1.00 21,612,776 8.92 $ 0.21 3,620,124 $ 0.35 $1.01–$2.00 45,000 2.25 1.40 45,000 1.40 $2.01–$3.00 – – – – – $3.01–$4.00 – – – – – $4.01–$5.00 – – – – – 21,657,776 8.90 $ 0.21 3,665,124 $ 0.37 Aggregate intrinsic value $ 0 $ 0 The aggregate intrinsic value in the preceding table is based on the last reported price at which the Company’s common stock traded on December 31, 2015, of $ 0.0585 2015 2014 Weighted Avg. Weighted Avg. Exercise Exercise Shares Price Shares Price Non-vested options, beginning of year 2,878,739 $ 0.37 5,295,300 $ 0.38 Granted 18,193,027 0.17 137,000 0.35 Vested (2,038,435) 0.33 (1,360,436) 0.38 Forfeited (1,040,679) 0.17 (1,193,125) 0.38 Non-vested options, end of year 17,992,652 $ 0.18 2,878,739 $ 0.37 Year Ended December 31, 2015 2014 Stock option grants beginning of period $ 730,102 $ 492,332 Stock-based arrangements during the period: Stock option grants 157,932 1,166 Restricted stock issued: Employee stock purchase plan 4,053 5,437 Director agreements –– –– $ 892,087 $ 498,935 As of December 31, 2015 and 2014, there was approximately $ 2,248,591 835,551 3.11 2.6

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plan	Note 12—Employee Benefit Plan The Company sponsors a profit sharing plan covering substantially all of its employees. The profit sharing plan allows for pre-tax employee contributions. The Company may, at the discretion of the Board of Directors, match a portion of the participant contributions. The Company currently contributes 25 1,500 2,239 7,105

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Note 13—Income Taxes For the years ended December 31, 2015 and 2014, the Company recorded no tax provision or benefit. While the Company has incurred losses from operations it has not recorded an income tax benefit for 2015 or 2014 as it has recorded a valuation allowance against net operating losses and other net deferred tax assets due to uncertainties related to the ability of these tax assets to be realized. Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted federal and state tax rates in effect for the year in which the differences are expected to reverse. 2015 2014 Deferred tax asset: Tax effect of: Net operating loss carryforwards $ 29,122,000 $ 26,754,000 Accrued expenses 87,000 105,000 Amortization of definite lived intangible assets 10,000 12,000 Non-qualified stock option compensation 315,000 113,000 Depreciation 72,000 97,000 Deferred revenue 880,000 930,000 Other 139,000 146,000 Patents (23,000) (77,000) State net operating loss carryforwards, net of federal tax benefit 579,000 214,000 Research tax credit carryforwards 2,274,000 2,169,000 Total deferred tax assets 33,455,000 30,463,000 Valuation allowance (33,455,000) (30,463,000) Net deferred tax assets $ - $ - As of December 31, 2015, the Company had gross net operating loss (NOL) and research tax credit carryforwards of approximately $ 88.2 1.6 88.2 2.5 As of December 31, 2015, the Company had gross NOL and research tax credit carryforwards of approximately $ 11.0 1.0 2035 The Company’s ability to use its NOL and tax credit carryforwards to reduce future taxes is subject to the restrictions provided by Section 382 of the Internal Revenue Code of 1986. These restrictions provide for limitations on the Company’s utilization of its NOL and tax credit carryforwards following a greater than 50 The Company is subject to taxation in the United States and the Commonwealth of Massachusetts. As of December 31, 2015, tax years for 2012, 2013 and 2014 are subject to examination by the tax authorities. As of December 31, 2015 we are no longer subject to U.S. federal and state examinations by tax authorities for years before 2012. 2015 2014 Tax at statutory rate (34.0) % (34.0) % State taxes, net of federal benefit 0.0 0.0 Research and development credit (1.3) (1.4) Share based payment expense 1.6 1.8 Other 0.7 1.5 Removal of deferred tax asset on federal net operating losses 0.0 0.0 Establishment of deferred tax asset on state net operating losses and state deferred taxes, net of federal income tax benefits (4.9) (3.8) Change in valuation allowance 37.9 36.0 Effective tax rate 0.0 % 0.0 %

Risks and Uncertainties

Risks and Uncertainties	12 Months Ended
	Dec. 31, 2015
Risks and Uncertainties [Abstract]
Risks and Uncertainties	Note 14—Risks and Uncertainties The Company develops genetic risk assessment tests and performs research for its own benefit. As of December 31, 2015, the Company has introduced four genetic risk assessment tests commercially. Commercial success of the Company’s genetic risk assessment tests will depend on their success as being deemed to be scientifically credible and cost-effective by consumers and the marketing success of the Company and its collaborative partners. Research in the field of disease predisposing genes and genetic markers is intense and highly competitive. The Company has many competitors in the United States and abroad that have considerably greater financial, technical, marketing, and other resources available. If the Company does not discover disease predisposing genes or genetic markers and develop risk assessment tests and launch such services or products before its competitors, then the potential for significant revenues may be reduced or eliminated. During the years ended December 31, 2015 and 2014, approximately 45 44 13 32

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Event	Note 15—Subsequent Event Effective February 1, 2016, the Company entered into an agreement with Metagenics, Inc., pursuant to which the Company will provide genetic testing and patient education to Metagenics employees, as well as dental professional support to their dental providers.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Significant Accounting Policies [Abstract]
Management Estimates	Management Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reported periods. Actual results could differ from those estimates. The Company’s most critical accounting policies are more fully discussed in these notes to the financial statements.
Revenue Recognition	Revenue Recognition Revenue from genetic testing services is recognized when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test. To the extent that tests have been prepaid but results have not yet been reported, recognition of all related revenue is deferred. As of December 31, 2015 and December 31, 2014, the Company had deferred genetic test revenue of $ 3.2 3.2 2.6 0.3 2.3 3.3 The Company recognizes breakage revenue related to genetic test kits utilizing the remote method. Under the remote method, breakage revenue should be recognized when the likelihood of the customer exercising rights of redemption becomes remote. The term remote requires statistical analysis of customer redemption patterns for all tests sold and returned. The Company analyzed redemption patterns from 2009 through 2015 and determined the period of time after which the likelihood of test redemption was remote was three years after the sale of a genetic test kit. Included in genetic test revenue in the years ended December 31, 2015 and 2014 is $ 218,000 309,000
Sales Commissions	Sales Commission On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor Inc. (“Alticor”). Pursuant to this Agreement, Amway Global sells the Company’s Inherent Health ® 302,000 218,000
Accounts Receivable	Accounts receivable is stated at estimated net realizable value, which is generally the invoiced amount less any estimated discount related to payment terms. The Company offers its commercial genetic test customers a 2
Inventory	Inventory Inventory is carried at lower of cost (first-in, first-out method) or market and no inventory reserve is deemed necessary at December 31, 2015. As the Company does not manufacture any products, no overhead costs are included in inventory. The Company has contracted with a fulfillment provider to supply its PerioPredict ® ® 33,000 ® ® December 31, 2015 December 31, 2014 Raw materials $ 112,372 $ 163,239 Finished goods 12,211 8,336 Total inventory, net $ 124,583 $ 171,575
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation expense in accordance with FASB ASC 718, Compensation – Stock Compensation
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes Significant management judgment is required in determining the Company’s provision (benefit) for income taxes, its deferred tax assets and liabilities and any valuation allowance recorded against deferred tax assets. The Company has recorded a full valuation allowance against its deferred tax assets of approximately $ 33.5 As a result of the Company’s change in its capital structure during the quarters ended June 30, 2013 and December 31, 2014, the Company may have undergone IRC section 382 ownership changes which would limit its ability to realize the benefit of its tax attributes (i.e., federal/state net operating losses and research and development credits) during their respective carry forward periods. Furthermore, pursuant to the change in capital structure in the quarter ended June 30, 2013, the Company realized cancellation of indebtedness income under IRC section 108(e)(8), which reduced the Company’s federal net operating loss carry-forward pursuant to IRC section 108(b)(2)(A), due to the fact that the Company’s liabilities exceeded the fair market value of its assets. Accordingly, the Company had a reduction in its deferred tax asset and a corresponding reduction in its valuation allowance for the quarter ending June 30, 2013. The cancellation of indebtedness income resulted from a shareholder’s conversion of debt of approximately $ 14.3 The Company reviews its recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. The Company reviews all material tax positions for all years open to statute to determine whether it is more likely than not that the positions taken would be sustained based on the technical merits of those positions. The Company did not recognize any adjustments for uncertain tax positions as of and during the year ended December 31, 2015. However, if the Company incurred interest and penalties they would be recorded in general and administrative expenses.
Research and Development	Research and Development Research and development costs are expensed as incurred.
Basic and Diluted Net Loss per Common Share	Basic and Diluted Net Loss per Common Share The Company applies the provisions of FASB ASC 260, Earnings per Share As of December 31, 2015 2014 Options outstanding 21,657,776 4,523,900 Warrants outstanding 88,301,079 89,951,079 Total 109,958,855 94,474,979
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. During the years ended December 31, 2015 and 2014, there were no items other than net loss included in the determination of comprehensive loss.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company, using available market information, has determined the estimated fair values of financial instruments. The stated values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to the short term nature of these instruments. The fair value of warrants is calculated using the Black-Scholes pricing model.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company maintains its cash and cash equivalents with domestic financial institutions that the Company believes to be of high credit standing. The Company believes that, as of December 31, 2015, its concentration of credit risk related to cash and cash equivalents was not significant. Cash and cash equivalents are available on demand and are generally in excess of FDIC insurance limits.
Fixed Assets	Fixed Assets Fixed assets are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided using the straight-line method over estimated useful lives of three to five years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease. Assets that have not yet been placed in service, have the costs incurred presented as part of Projects in Progress. Once the asset has been placed in service, the related costs are transferred to the appropriate category and depreciation commences. There are no items in Projects in Process for the year ended December 31, 2015.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates its long-lived assets, including intangible assets, for impairment whenever events or changes in circumstances indicate that carrying amounts of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. Any write-downs, based on fair value, are to be treated as permanent reductions in the carrying amount of the assets. For the year ended December 31, 2015, the Company recorded a write down of $ 66,000
Segment Reporting	Segment Reporting As of December 31, 2015 and 2014, the Company has one segment, the genetic test business. The Company develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive measures. The Company’s principal operations and markets are located in the United States.
Recent Accounting Pronouncements	Recent Accounting Pronouncements FASB ASU 2015-03 - Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. In April 2015, the FASB issued ASU No. 2015-03, which requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts. Prior to the amendments, debt issuance costs were presented as a deferred charge (i.e., an asset) on the balance sheet. Further, the amendments require the amortization of debt issuance costs to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate on the debt. The amendments are effective for public business entities for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The amendments must be applied retrospectively. All entities have the option of adopting the new requirements as of an earlier date for financial statements that have not been previously issued. The Company does not expect this ASU to have a material impact on its consolidated financial statements. FASB ASC 606 ASU 2014-09 - Revenue from contracts with customers. In May 2014, the FASB issued amended guidance on contracts with customers to transfer goods or services or contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). The guidance requires an entity to recognize revenue on contracts with customers to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance requires that an entity depict the consideration by applying the following five steps: ⋅ Identify the contract(s) with a customer. ⋅ Identify the performance obligations in the contract. ⋅ Determine the transaction price. ⋅ Allocate the transaction price to the performance obligations in the contract. ⋅ Recognize revenue when (or as) the entity satisfies a performance obligation. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. This amendment is to be either retrospectively adopted to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. The Company is evaluating the impact of the adoption of this guidance to determine whether or not it has a material impact on the Company's financial statements. In April 2015, the FASB voted to defer the required implementation date of ASU 2014-09 to December 2017. Public companies may elect to adopt the standard along the original timeline. We are evaluating the impact of the adoption of this guidance to determine whether or not it has a material impact on the Company's financial statements. FASB ASC 606 ASU 2014-15 - Presentation of Financial Statements—Going Concern (Subtopic 205-40); Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern . In August 2014, the FASB issued ASU No. 2014-15, which applies should a company be facing probable liquidation within one year of the issuance of the financial statements, but is not actually in liquidation at the time of issuance. The applicable basis for presentation remains as a going concern, but if liquidation within one year is probable, then certain disclosures must be included in the financial statement presentation. ASU 2014-15 is effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. The Company is not electing to adopt early and is evaluating the impact of ASU 2014-15 on the Company’s financial disclosures.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Significant Accounting Policies [Abstract]
Inventory	Inventory consisted of the following at December 31, 2015 and 2014: December 31, 2015 December 31, 2014 Raw materials $ 112,372 $ 163,239 Finished goods 12,211 8,336 Total inventory, net $ 124,583 $ 171,575
Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share	Potential common stock equivalents excluded from the calculation of diluted net loss per share are as follows: As of December 31, 2015 2014 Options outstanding 21,657,776 4,523,900 Warrants outstanding 88,301,079 89,951,079 Total 109,958,855 94,474,979

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Assets [Abstract]
Schedule of useful lives and balances of fixed assets	The useful lives and balances of fixed assets at December 31, 2015 and 2014 consisted of the following: Useful Life 2015 2014 Computer software, computer equipment and office equipment 3 years $ 516,511 $ 477,222 Laboratory equipment 5 years 1,887,454 1,837,504 Furniture and fixtures 5 years 40,349 40,349 Leasehold improvements 5 years 309,618 309,618 Website development 3 years 298,553 298,553 Projects in Progress — 6,750 3,052,485 2,969,996 Less — Accumulated depreciation and amortization (2,408,585) (2,196,217) Total $ 643,900 $ 773,779

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Intangible Assets [Abstract]
Summary of Intangible Assets	Intangible assets at December 31, 2015 and 2014 consisted of the following: 2015 2014 Patent costs $ 1,154,523 $ 1,154,523 Less — Accumulated amortization (1,029,497) (958,758) Less — Write off related to patents no longer in use (66,147) — Total $ 58,879 $ 195,765
Patent Costs Amortized on a Straight-Line Basis	10 Year ended December 31, 2016 33,450 2017 19,117 2018 6,312 $ 58,879

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2015
Accrued Liabilities, Current [Abstract]
Schedule of accrued expenses	Accrued expenses at December 31, 2015 and 2014 consisted of the following: 2015 2014 Payroll and vacation $ 412,674 $ 328,972 Other 85,014 14,253 Total accrued expenses $ 497,688 $ 343,225

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum lease commitments under non-cancelable lease agreements with initial or remaining terms of one year or more at December 31, 2015, are as follows: Year Ended Office Total December 31, Office Lease Copier Lease Net Lease Equipment Payments, Net 2016 326,349 6,624 332,973 2,226 335,199 2017 81,993 6,624 88,617 2,226 90,843 2018 — 1,104 1,104 1,484 2,588 $ 408,342 14,352 $ 422,694 $ 5,936 $ 428,630

Capital Stock (Tables)

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2015
Authorized, Issued and Reserved shares of common stock	172,887,221 Reserved for issuance Strike Price Expiry Shares reserved under outstanding stock options and options available for grant 52,307,279 Shares reserved for future issuance under the Employee Stock Purchase Plan 300,073 Warrants to purchase common stock associated with December 2014 private placement 50,189,431 $ 0.1003 December 23, 2021 Warrants to purchase common stock associated with December 2014 venture loan and security agreement 2,492,523 $ 0.1003 December 23, 2024 Warrants to purchase common stock associated with September 2014 consulting agreement with Danforth Advisors 100,000 $ 0.2500 September 8, 2024 Outstanding warrants issued in June 2012 437,158 $ 0.2745 June 29, 2017 Outstanding warrants issued in May 2013, vesting May 2013 20,655,737 $ 0.2745 May 17, 2020 Outstanding warrants issued in May 2013, vesting August 2013 14,426,230 $ 0.2745 August 9, 2020 Total common shares reserved for issuance at December 31, 2015 140,908,431 Total common shares issued and outstanding at December 31, 2015 172,887,221 Total common shares outstanding and reserved for issuance at December 31, 2015 313,795,652
Principal payments due under the terms of Loan Agreement	Principal payments due under the terms of the Loan Agreement are as follows: 2016 1,333,333 2017 2,000,000 2018 1,666,667 $ 5,000,000
Venture Loan [Member]
Black-Scholes Pricing Model Assumptions to Determine Fair Value of Warrants	Fair value of the Lender Warrants was calculated using the following inputs in a Black-Scholes model: December 23, 2014 Risk-free interest rate 2.17 % Expected life 10 years Expected volatility 121.6 % Dividend yield 0 %
Placement Agent Warrants 2014 [Member]
Black-Scholes Pricing Model Assumptions to Determine Fair Value of Warrants	The 2014 Warrants were recorded as equity at fair value on the date of issuance. Fair value of the 2014 Warrants was calculated using the following inputs in a Black-Scholes model: December 23, 2014 Risk-free interest rate 1.98 % Expected life 7 years Expected volatility 138.4 % Dividend yield 0 %

Stock-Based Compensation Arra30

Stock-Based Compensation Arrangements (Tables)	12 Months Ended
	Dec. 31, 2015
Stock-Based Compensation Arrangements [Abstract]
Stock-based compensation expense for stock option awards	For purposes of determining the stock-based compensation expense for stock option awards in 2015 and 2014, the Black-Scholes option-pricing model was used with the following weighted-average assumptions: 2015 2014 Risk-free interest rate 1.54 % 1.53 % Expected life 5.73 years 5.73 years Expected volatility 138.80 % 144.74 % Dividend yield 0 % 0 %
Common Stock Weighted Average Purchase Price	The following table details stock option and restricted stock activity for the years ended December 31, 2015 and 2014. 2015 2014 Weighted Avg. Weighted Avg. Exercise Exercise Shares Price Shares Price Outstanding, beginning of period 4,523,900 $ 0.39 5,884,050 $ 0.43 Granted 18,193,027 0.17 137,000 0.35 Stock options exercised –– 0.00 –– 0.00 Restricted stock exercised –– 0.00 –– 0.00 Forfeited/Expired (1,059,151) 0.17 (1,497,150) 0.53 Outstanding, end of period 21,657,776 $ 0.21 4,523,900 $ 0.39 Exercisable, end of period 3,665,124 $ 0.32 1,645,161 $ 0.43
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range	The following table details further information regarding stock options and restricted stock outstanding and exercisable at December 31, 2015: Stock Options/Restricted Stock Stock Options/Restricted Stock Outstanding Exercisable Weighted Avg. remaining Weighted Avg. Weighted Avg. contractual life Exercise Exercise Range of Exercise Price: Shares (years) Price Shares Price $0.01–$1.00 21,612,776 8.92 $ 0.21 3,620,124 $ 0.35 $1.01–$2.00 45,000 2.25 1.40 45,000 1.40 $2.01–$3.00 – – – – – $3.01–$4.00 – – – – – $4.01–$5.00 – – – – – 21,657,776 8.90 $ 0.21 3,665,124 $ 0.37 Aggregate intrinsic value $ 0 $ 0
Schedule Of Non-Vested Options	The following table summarizes the status of the Company’s non-vested options for the years ended December 31, 2015 and 2014: 2015 2014 Weighted Avg. Weighted Avg. Exercise Exercise Shares Price Shares Price Non-vested options, beginning of year 2,878,739 $ 0.37 5,295,300 $ 0.38 Granted 18,193,027 0.17 137,000 0.35 Vested (2,038,435) 0.33 (1,360,436) 0.38 Forfeited (1,040,679) 0.17 (1,193,125) 0.38 Non-vested options, end of year 17,992,652 $ 0.18 2,878,739 $ 0.37
Total Compensation Cost Recorded for Stock-Based Compensation	Total cost for stock-based compensation arrangements is as follows: Year Ended December 31, 2015 2014 Stock option grants beginning of period $ 730,102 $ 492,332 Stock-based arrangements during the period: Stock option grants 157,932 1,166 Restricted stock issued: Employee stock purchase plan 4,053 5,437 Director agreements –– –– $ 892,087 $ 498,935

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities	As of December 31, 2015 and 2014, the expected income tax effect of the Company’s deferred tax assets (liabilities) consisted of the following: 2015 2014 Deferred tax asset: Tax effect of: Net operating loss carryforwards $ 29,122,000 $ 26,754,000 Accrued expenses 87,000 105,000 Amortization of definite lived intangible assets 10,000 12,000 Non-qualified stock option compensation 315,000 113,000 Depreciation 72,000 97,000 Deferred revenue 880,000 930,000 Other 139,000 146,000 Patents (23,000) (77,000) State net operating loss carryforwards, net of federal tax benefit 579,000 214,000 Research tax credit carryforwards 2,274,000 2,169,000 Total deferred tax assets 33,455,000 30,463,000 Valuation allowance (33,455,000) (30,463,000) Net deferred tax assets $ - $ -
Schedule of Effective Income Tax Rate Reconciliation	The benefit for income taxes differs from the federal statutory rate due to the following: 2015 2014 Tax at statutory rate (34.0) % (34.0) % State taxes, net of federal benefit 0.0 0.0 Research and development credit (1.3) (1.4) Share based payment expense 1.6 1.8 Other 0.7 1.5 Removal of deferred tax asset on federal net operating losses 0.0 0.0 Establishment of deferred tax asset on state net operating losses and state deferred taxes, net of federal income tax benefits (4.9) (3.8) Change in valuation allowance 37.9 36.0 Effective tax rate 0.0 % 0.0 %

Operating Matters and Liquidi32

Operating Matters and Liquidity - Additional Information (Detail) - USD ($)	1 Months Ended		12 Months Ended
	Dec. 23, 2014	May. 17, 2013	Dec. 31, 2015	Dec. 31, 2014	Jun. 30, 2014
Line of Credit Facility [Line Items]
Net Income Loss			$ (7,898,013)	$ (6,335,714)
Accumulated deficit			(128,988,325)	(121,090,312)
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.2745
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					13,661,201
December 2014 Private Placement [Member]
Line of Credit Facility [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	50,099,700
Sale of Stock, Price Per Share	$ 0.1003
Sale of Stock, Consideration Received on Transaction	$ 5,025,000
2013 Warrants [Member]
Line of Credit Facility [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.2745
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		32,786,885
2014 warrants [Member]
Line of Credit Facility [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.1003
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	50,099,700
Common Stock [Member]
Line of Credit Facility [Line Items]
Net Income Loss			$ 0	$ 0
Common Stock [Member] | May 2013 Private Placement [Member]
Line of Credit Facility [Line Items]
Sale of Stock, Number of Shares Issued in Transaction		43,715,847
Sale of Stock, Price Per Share		$ 0.2745
Sale of Stock, Consideration Received on Transaction		$ 12,000,000

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Schedule Of Inventory) (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Line Items]
Raw materials	$ 112,372	$ 163,239
Finished goods	12,211	8,336
Total inventory, net	$ 124,583	$ 171,575

Summary of Significant Accoun34

Summary of Significant Accounting Policies (Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share) (Detail) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the calculation of diluted net loss per share	109,958,855	94,474,979
Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the calculation of diluted net loss per share	21,657,776	4,523,900
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents excluded from the calculation of diluted net loss per share	88,301,079	89,951,079

Summary of Significant Accoun35

Summary of Significant Accounting Policies- Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Significant Accounting Policies [Line Items]
Deferred revenue	$ 3,200,000	$ 3,200,000
Sales commissions	$ 302,000	218,000
Percentage of cash discount offered to customers	2.00%
Deferred tax assets, valuation allowance	$ 33,455,000	30,463,000
Convertible Debt	14,300,000
Impairment of Intangible Assets, Finite-lived	66,000
ABG [Member]
Significant Accounting Policies [Line Items]
Purchase Order Placed	3,300,000
Fulfillment Center [Member]
Significant Accounting Policies [Line Items]
Payments To Acquire of Inventory	33,000
Genetic Test Revenue [Member]
Significant Accounting Policies [Line Items]
Breakage Revenue	218,000	$ 309,000
Customer Payment [Member]
Significant Accounting Policies [Line Items]
Deferred revenue	300,000
Kits Components [Member]
Significant Accounting Policies [Line Items]
Deferred revenue	2,600,000
Distributors [Member]
Significant Accounting Policies [Line Items]
Deferred revenue	$ 2,300,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Oct. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Prior Period Notice		60 days
Business Combination, Consideration Transferred	$ 250,000
Amway Global [Member]
Business Acquisition [Line Items]
Commissions paid		$ 302,000	$ 218,000
Amway Global [Member] | Sales [Member]
Business Acquisition [Line Items]
Concentration Risk, Percentage		45.00%	44.00%
Access Business Group International Llc [Member]
Business Acquisition [Line Items]
Proceeds from License Fees Received		$ 191,000	$ 150,000
ABG [Member]
Business Acquisition [Line Items]
Purchase Order Placed		3,300,000
Payments to Acquire Businesses, Gross		$ 519,000
ABG [Member] | Sales [Member]
Business Acquisition [Line Items]
Concentration Risk, Percentage		13.00%	32.00%
ABG [Member] | 2014 Program [Member]
Business Acquisition [Line Items]
Purchase Order Received				$ 1,800,000
ABG [Member] | 2013 Program [Member]
Business Acquisition [Line Items]
Purchase Order Received				$ 1,500,000

Debt Instruments - Additional I

Debt Instruments - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 23, 2014	Dec. 31, 2015	Dec. 31, 2014	Jun. 30, 2014
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				13,661,201
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.2745
Interest Paid		$ 467,500	$ 0
Venture Loan [Member]
Debt Instrument [Line Items]
Proceeds from Issuance of Long-term Debt	$ 5,000,000
Debt Instrument, Description of Variable Rate Basis	The loan bears interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeds 0.50%, the interest rate will be adjusted by an amount equal to the difference between such rates at the end of that particular month.
Debt Instrument, Interest Rate, Stated Percentage	9.00%
Debt Instrument, Payment Terms	The loan is to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan, or $225,000, will be due and payable.
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,492,523
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.1003
Warrants Expire Term	10 years
Interest Expense, Debt	$ 89,000
Intrinsic Value Of Warrants	261,000
Interest Expense, Other	$ 225,000
Debt Instrument, Unamortized Discount		257,000
Interest Paid		456,000	11,000
Paid-in-Kind Interest		$ 153,000	$ 0

Fixed Assets (Detail)

Fixed Assets (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Computer software, computer equipment and office equipment	3 years
Laboratory equipment, Useful Life	5 years
Furniture and fixtures, Useful Life	5 years
Leasehold improvements, Useful Life	5 years
Website development, Useful Life	3 years
Computer software, computer equipment and office equipment	$ 516,511	$ 477,222
Laboratory equipment	1,887,454	1,837,504
Furniture and fixtures	40,349	40,349
Leasehold improvements	309,618	309,618
Website development	298,553	298,553
Projects in progress	0	6,750
Property, Plant and Equipment, Gross	3,052,485	2,969,996
Less — Accumulated depreciation and amortization	(2,408,585)	(2,196,217)
Total	$ 643,900	$ 773,779

Fixed Assets - Additional Infor

Fixed Assets - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Utilities Operating Expense, Depreciation and Amortization	$ 212,000	$ 169,000

Intangible Assets (Schedule of

Intangible Assets (Schedule of Intangible Assets) (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Schedule of Intangible Assets Disclosure [Line Items]
Patent costs	$ 1,154,523	$ 1,154,523
Less - Accumulated amortization	(1,029,497)	(958,758)
Finite-lived Intangible Assets Write Off	(66,147)	0
Total	$ 58,879	$ 195,765

Intangible Assets (Patent Costs

Intangible Assets (Patent Costs Amortized on Straight-Line Basis) (Detail)	Dec. 31, 2015USD ($)
Expected Amortization Expense [Line Items]
2,016	$ 33,450
2,017	19,117
2,018	6,312
Finite-Lived Intangible Assets, Net, Total	$ 58,879

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Schedule of Intangible Assets Disclosure [Line Items]
Patent amortization expense	$ 136,886	$ 94,100
Patent life	10 years

Accrued Expenses (Detail)

Accrued Expenses (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Payroll and vacation	$ 412,674	$ 328,972
Other	85,014	14,253
Total accrued expenses	$ 497,688	$ 343,225

Commitments and Contingencies44

Commitments and Contingencies (Detail)	Dec. 31, 2015USD ($)
2,016	$ 335,199
2,017	90,843
2,018	2,588
Operating Leases, Future Minimum Payments Due	428,630
Office Lease [Member]
2,016	326,349
2,017	81,993
2,018	0
Operating Leases, Future Minimum Payments Due	408,342
Copier Lease [Member]
2,016	6,624
2,017	6,624
2,018	1,104
Operating Leases, Future Minimum Payments Due	14,352
Net Lease [Member]
2,016	332,973
2,017	88,617
2,018	1,104
Operating Leases, Future Minimum Payments Due	422,694
Office Equipment [Member]
2,016	2,226
2,017	2,226
2,018	1,484
Operating Leases, Future Minimum Payments Due	$ 5,936

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	Apr. 06, 2015	Nov. 12, 2008	Jan. 31, 2015	Oct. 31, 2013	Dec. 31, 2012	May. 31, 2011	Apr. 30, 2010	Mar. 31, 2010	Dec. 31, 2015	Dec. 31, 2014	Feb. 26, 2014
Loss Contingencies [Line Items]
Operating Leases, Rent Expense									$ 352,682	$ 309,891
Property Under Commercial Lease And Sublease Details									On February 7, 2014, the Company entered into the Second Amendment to Commercial Lease which, among other things a) extended the term of the lease from March 31, 2014 to March 31, 2017; b) reduced the 19,000 square feet, the amount of space under the master lease, by approximately 6,011 square feet, to approximately 13,000 square feet, which is the amount of space the Company currently occupies
Officers' Compensation									$ 360,000
Granted, Weighted Avg.Exercise Price									$ 0.17	$ 0.35
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price									$ 0.32	$ 0.43
Employee-related Liabilities, Current											$ 166,000
Operating Leases Base rent In Year Two									2.06%
Operating Leases Base Rent In Year Three									2.06%
Dr. Kornman [Member]
Loss Contingencies [Line Items]
Officers' Compensation									$ 360,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross		75,000	2,030,000	2,250,000	300,000	100,000	30,000		400,000
Granted, Weighted Avg.Exercise Price		$ 0.48	$ 0.26	$ 0.3799					$ 0.07
Annual Reimbursement For Payment Of Life Insurance Premiums									$ 3,296
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price					$ 0.34	$ 0.46	$ 0.745
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						25.00%	20.00%
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award									If at any time within the 90 days prior to or 12 months following the effective date of a Change in Control, Dr. Kornman is terminated without Cause (as such terms are defined in the Agreement), this option shall become fully vested and .exercisable as of the date of termination, and the Company will pay him an amount equal to his base pay in effect at the time of such termination for a period commencing on the effective date of a release agreement and ending on the six moth anniversary of such effective date.
Dr. Kornman [Member] | Restricted Stock [Member]
Loss Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period								12,500
Dr. Kornman [Member] | First Anniversaries [Member]
Loss Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					25.00%
Dr. Kornman [Member] | Second Anniversaries [Member]
Loss Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					33.00%
Dr. Kornman [Member] | Third Anniversaries [Member]
Loss Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					42.00%
Chief Marketing Officer [Member]
Loss Contingencies [Line Items]
Officers' Compensation					$ 265,000
Chief Executive Officer [Member]
Loss Contingencies [Line Items]
Officers' Compensation	$ 365,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	14,245,227
Granted, Weighted Avg.Exercise Price	$ 0.1525
Percentage Of Bonus On Base Salary For Executives	35.00%
Percentage Of Stretch Bonus Of Target Bonus	150.00%
Percentage Of Shares To Be Vest	25.00%
Percentage Of Additional Shares To Be Vest	2.083%

Capital Stock (Authorized, Issu

Capital Stock (Authorized, Issued and Reserved shares of common stock) (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Jun. 30, 2014
Reserved for issuance	140,908,431
Strike Price		$ 0.2745
Total common shares issued and outstanding at December 31, 2015	172,887,221
Total common shares outstanding and reserved for issuance at December 31, 2015	313,795,652
Warrants with common stock additional purchase rights associated with December 2014 private placement [Member]
Reserved for issuance	50,189,431
Strike Price	$ 0.1003
Expiry	Dec. 23, 2021
Warrants to purchase common stock associated with September 2014 consulting agreement with Danforth Advisors [Member]
Reserved for issuance	100,000
Strike Price	$ 0.2500
Expiry	Sep. 8, 2024
Shares reserved under outstanding stock options and options available for grant [Member]
Reserved for issuance	52,307,279
Shares reserved for future issuance under the Employee Stock Purchase Plan [Member]
Reserved for issuance	300,073
Warrants to purchase common stock associated with December 2014 venture loan and security agreement [Member]
Reserved for issuance	2,492,523
Strike Price	$ 0.1003
Expiry	Dec. 23, 2024
Outstanding warrants issued in June 2012 [Member]
Reserved for issuance	437,158
Strike Price	$ 0.2745
Expiry	Jun. 29, 2017
Outstanding warrants issued in May 2013, vesting May 2013 [Member]
Reserved for issuance	20,655,737
Strike Price	$ 0.2745
Expiry	May 17, 2020
Outstanding warrants issued in May 2013, vesting August 2013 [Member]
Reserved for issuance	14,426,230
Strike Price	$ 0.2745
Expiry	Aug. 9, 2020

Capital Stock (Black Scholes mo

Capital Stock (Black Scholes model to determine the fair value of the warrants) (Detail)	1 Months Ended
	Dec. 23, 2014
2014 Placement Agent Warrants [Member]
Stockholders Equity [Line Items]
Risk-free interest rate	1.98%
Expected life	7 years
Expected volatility	138.40%
Dividend Yield	0.00%
Lender Warrants [Member]
Stockholders Equity [Line Items]
Risk-free interest rate	2.17%
Expected life	10 years
Expected volatility	121.60%
Dividend Yield	0.00%

Capital Stock (Principal paymen

Capital Stock (Principal payments due under the terms of the Loan Agreement) (Detail) - Loan Agreement	Dec. 31, 2015USD ($)
2,016	$ 1,333,333
2,017	2,000,000
2,018	1,666,667
Long-term Debt	$ 5,000,000

Capital Stock - Additional Info

Capital Stock - Additional Information (Detail) - USD ($)	1 Months Ended				12 Months Ended
	Dec. 23, 2014	Sep. 30, 2014	Jun. 30, 2014	May. 17, 2013	Dec. 31, 2015	Dec. 31, 2014	Aug. 09, 2013
Stockholders Equity [Line Items]
Convertible preferred stock, par value					$ 0.001	$ 0.001
Convertible preferred stock, shares authorized					6,000,000	6,000,000
Common stock, shares authorized					450,000,000	300,000,000
Common stock, par value					$ 0.001	$ 0.001
Common stock, shares outstanding					172,887,221	172,683,342
Allocated Share-based Compensation Expense					$ 12,000	$ 3,000
Warrants exercise price per share			$ 0.2745
Common Stock Shares Issued					172,887,221	172,683,342
Share Price			$ 0.2745
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			13,661,201
Interest Paid					$ 467,500	$ 0
Stock Issued During Period, Shares, New Issues			18,214,936
May 2013 Private Placement [Member] | Minimum [Member]
Stockholders Equity [Line Items]
Common stock, shares authorized							150,000,000
May 2013 Private Placement [Member] | Maximum [Member]
Stockholders Equity [Line Items]
Common stock, shares authorized							300,000,000
Venture Loan [Member]
Stockholders Equity [Line Items]
Warrants exercise price per share	$ 0.1003
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,492,523
Warrants and Rights Outstanding	$ 261,000
Proceeds from Issuance of Long-term Debt	$ 5,000,000
Interest Paid					456,000	11,000
Paid-in-Kind Interest					153,000	$ 0
Debt Instrument, Unamortized Discount					$ 257,000
Warrants Expire Term	10 years
Investor [Member]
Stockholders Equity [Line Items]
Sale of Stock, Consideration Received on Transaction	$ 5,025,000
Sale of Stock, Number of Shares Issued in Transaction	50,099,700
Warrants exercise price per share	$ 0.1003
Sale of Stock, Price Per Share	$ 0.1003
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	50,099,700
Danforth Advisors [Member]
Stockholders Equity [Line Items]
Common stock, par value		$ 0.25
Warrants Fair Value Disclosure		$ 24,000
Common Stock Shares Issued		100,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		50.00%
Common Stock [Member]
Stockholders Equity [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion					39,089,161
Stock Issued During Period, Shares, New Issues						50,099,700
Common Stock [Member] | May 2013 Private Placement [Member]
Stockholders Equity [Line Items]
Sale of Stock, Consideration Received on Transaction				$ 12,000,000
Sale of Stock, Number of Shares Issued in Transaction				43,715,847
Sale of Stock, Price Per Share				$ 0.2745
Warrants 2013 [Member]
Stockholders Equity [Line Items]
Percentage Of Warrants Exercisable				63.00%
Percentage Of Warrants Exercisable After Shareholder Approval				37.00%
Warrants exercise price per share				$ 0.2745
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				32,786,885
Warrants 2014 [Member]
Stockholders Equity [Line Items]
Warrants and Rights Outstanding						$ 5,200,000
Placement Agent Warrants [Member]
Stockholders Equity [Line Items]
Allocated Share-based Compensation Expense					$ 780,000
Warrants To Purchase Of Common Stock					2,295,082
Warrants exercise price per share					$ 0.2745
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					89,731
Warrants and Rights Outstanding						$ 9,000
Payments for Underwriting Expense					$ 218,000

Stock-Based Compensation Arra50

Stock-Based Compensation Arrangements (Stock-based compensation expense for stock option awards) (Detail)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Risk-free interest rate	1.54%	1.53%
Expected life	5 years 8 months 23 days	5 years 8 months 23 days
Expected volatility	138.80%	144.74%
Dividend yield	0.00%	0.00%

Stock-Based Compensation Arra51

Stock-Based Compensation Arrangements (Stock Option and Restricted Stock Grants) (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Shares
Outstanding, beginning of period	4,523,900	5,884,050
Granted	18,193,027	137,000
Stock options exercised	0	0
Restricted stock exercised	0	0
Forfeited/Expired	(1,059,151)	(1,497,150)
Outstanding, end of period	21,657,776	4,523,900
Exercisable, end of period	3,665,124	1,645,161
Weighted Avg. Exercise Price
Outstanding, beginning of period	$ 0.39	$ 0.43
Granted	0.17	0.35
Stock options exercised	0	0
Restricted stock exercised	0	0
Forfeited/Expired	0.17	0.53
Outstanding, end of period	0.21	0.39
Exercisable, end of period	$ 0.32	$ 0.43

Stock-Based Compensation Arra52

Stock-Based Compensation Arrangements (Stock options and restricted stock outstanding and exercisable) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding, Shares	21,657,776	4,523,900	5,884,050
Outstanding, Weighted Avg. Exercise Price	$ 0.21	$ 0.39	$ 0.43
Exercisable, Shares	3,665,124	1,645,161
Exercisable, Weighted Avg. Exercise Price	$ 0.32	$ 0.43
Stock Option Or Restricted Stock Outstanding [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding, Shares	21,657,776
Outstanding, Weighted Avg. remaining contractual life	8 years 10 months 24 days
Outstanding, Weighted Avg. Exercise Price	$ 0.21
Aggregate intrinsic value	$ 0
Stock Option Or Restricted Stock Outstanding [Member] | $0.01-$1.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding, Shares	21,612,776
Outstanding, Weighted Avg. remaining contractual life	8 years 11 months 1 day
Outstanding, Weighted Avg. Exercise Price	$ 0.21
Stock Option Or Restricted Stock Outstanding [Member] | $1.01-$2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding, Shares	45,000
Outstanding, Weighted Avg. remaining contractual life	2 years 3 months
Outstanding, Weighted Avg. Exercise Price	$ 1.40
Stock Option Or Restricted Stock Outstanding [Member] | $2.01-$3.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding, Shares	0
Outstanding, Weighted Avg. remaining contractual life	0 years
Outstanding, Weighted Avg. Exercise Price	$ 0
Stock Option Or Restricted Stock Outstanding [Member] | $3.01-$4.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding, Shares	0
Outstanding, Weighted Avg. remaining contractual life	0 years
Outstanding, Weighted Avg. Exercise Price	$ 0
Stock Option Or Restricted Stock Outstanding [Member] | $4.01-$5.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Outstanding, Shares	0
Outstanding, Weighted Avg. remaining contractual life	0 years
Outstanding, Weighted Avg. Exercise Price	$ 0
Stock Option Or Restricted Stock Exercisable [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercisable, Shares	3,665,124
Exercisable, Weighted Avg. Exercise Price	$ 0.37
Aggregate intrinsic value	$ 0
Stock Option Or Restricted Stock Exercisable [Member] | $0.01-$1.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercisable, Shares	3,620,124
Exercisable, Weighted Avg. Exercise Price	$ 0.35
Stock Option Or Restricted Stock Exercisable [Member] | $1.01-$2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercisable, Shares	45,000
Exercisable, Weighted Avg. Exercise Price	$ 1.40
Stock Option Or Restricted Stock Exercisable [Member] | $2.01-$3.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercisable, Shares	0
Exercisable, Weighted Avg. Exercise Price	$ 0
Stock Option Or Restricted Stock Exercisable [Member] | $3.01-$4.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercisable, Shares	0
Exercisable, Weighted Avg. Exercise Price	$ 0
Stock Option Or Restricted Stock Exercisable [Member] | $4.01-$5.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercisable, Shares	0
Exercisable, Weighted Avg. Exercise Price	$ 0

Stock-Based Compensation Arra53

Stock-Based Compensation Arrangements (Non-vested options) (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Non-vested options, beginning of year	2,878,739	5,295,300
Non-vested options, beginning of year, Weighted Avg Exercise Price	$ 0.37	$ 0.38
Granted, Shares	18,193,027	137,000
Granted, Weighted Avg Exercise Price	$ 0.17	$ 0.35
Vested, Shares	(2,038,435)	(1,360,436)
Vested, Weighted Avg Exercise Price	$ 0.33	$ 0.38
Forfeited, Shares	(1,040,679)	(1,193,125)
Forfeited, Weighted Avg Exercise Price	$ 0.17	$ 0.38
Non-vested options, end of year, Shares	17,992,652	2,878,739
Non-vested options, end of year, Weighted Avg Exercise Price	$ 0.18	$ 0.37

Stock-Based Compensation Arra54

Stock-Based Compensation Arrangements (Stock-Based Compensation) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation	$ 892,087	$ 498,935
Stock option grants beginning of period [Member]
Share-based Compensation	730,102	492,332
Stock option grants [Member]
Share-based Compensation	157,932	1,166
Employee Stock Purchase Plan [Member]
Share-based Compensation	4,053	5,437
Director agreements [Member]
Share-based Compensation	$ 0	$ 0

Stock-Based Compensation Arra55

Stock-Based Compensation Arrangements - Additional Information (Detail) - USD ($)	Apr. 06, 2015	Jul. 21, 2015	Dec. 31, 2015	Dec. 31, 2014	Aug. 09, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average fair value			$ 0.16	$ 0.32
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Share-based Awards Other than Options			$ 2,248,591	$ 835,551
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value			$ 0.0585
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			3 years 1 month 10 days	2 years 7 months 6 days
Granted,Weighted Avg.Exercise Price			$ 0.17	$ 0.35
Employment Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	14,245,227
Granted,Weighted Avg.Exercise Price	$ 0.1525
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights			The options will vest as to 25% of the shares on April 6, 2016, and as to an additional 2.083% of the shares on the last day of each successive month thereafter, provided that he remains employed by Company on the vesting date.
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans			203,879	134,935
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock purchase price			85.00%
Weighted-average purchase price			$ 0.10	$ 0.24
Weighted-average fair value			$ 0.12	$ 0.28
Compensation expense			$ 4,053	$ 5,437
Employee Stock Purchase Plan [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans			203,879	134,935
2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Payment Award, Number of Shares Authorized					8,860,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		30,000,000	6,570,748
2013 Plan [Member] | Employment Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,622,948
2013 Plan [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			30,649,503
2004 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Payment Award, Number of Shares Authorized					2,435,500
Outside of 2013 Plan [Member] | Employment Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	11,622,279

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Defined Contribution Plan Employer Matching Contribution Vested Period	5 years
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	25.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount	$ 1,500
Defined Contribution Plan, Cost Recognized	$ 2,239	$ 7,105

Income Taxes (Deferred tax asse

Income Taxes (Deferred tax assets (liabilities) (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred tax asset:
Net operating loss carryforwards	$ 29,122,000	$ 26,754,000
Accrued expenses	87,000	105,000
Amortization of definite lived intangible assets	10,000	12,000
Non-qualified stock option compensation	315,000	113,000
Depreciation	72,000	97,000
Deferred revenue	880,000	930,000
Other	139,000	146,000
Patents	(23,000)	(77,000)
State net operating loss carryforwards, net of federal tax benefit	579,000	214,000
Research tax credit carryforwards	2,274,000	2,169,000
Total deferred tax assets	33,455,000	30,463,000
Valuation allowance	(33,455,000)	(30,463,000)
Net deferred tax assets	$ 0	$ 0

Income Taxes (Provision for inc

Income Taxes (Provision for income taxes) (Detail)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Tax at statutory rate	(34.00%)	(34.00%)
State taxes, net of federal benefit	0.00%	0.00%
Research and development credit	(1.30%)	(1.40%)
Share based payment expense	1.60%	1.80%
Other	0.70%	1.50%
Removal of deferred tax asset on federal net operating losses	0.00%	0.00%
Establishment of deferred tax asset on state net operating losses and state deferred taxes, net of federal income tax benefits	(4.90%)	(3.80%)
Change in valuation allowance	37.90%	36.00%
Effective tax rate	0.00%	0.00%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)
Income Taxes Disclosure [Line Items]
Operating Loss Carryforwards	$ 88.2
Equity Method Investment, Ownership Percentage	50.00%
Additional Paid-In Capital [Member]
Income Taxes Disclosure [Line Items]
Operating Loss Carryforwards	$ 88.2
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost	2.5
Research Tax Credit Carryforward [Member]
Income Taxes Disclosure [Line Items]
Tax Credit Carryforward, Amount	1.6
State and Local Jurisdiction [Member]
Income Taxes Disclosure [Line Items]
Operating Loss Carryforwards	$ 11
Operating Loss Carryforward Of Expiration Year	2,035
Tax Credit Carryforward, Amount	$ 1

Risks and Uncertainties - Addit

Risks and Uncertainties - Additional Information (Detail) - Sales Revenue, Net [Member]	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Merchant Network And Channel Partner [Member]
Concentration Risk [Line Items]
Sales Revenue Goods Net Percentage	45.00%	44.00%
ABG’s promotional product [Member]
Concentration Risk [Line Items]
Sales Revenue Goods Net Percentage	13.00%	32.00%